Related Experiment Video

Updated: May 29, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

Inactivation of glycogen synthase kinase-3β is required for osteoclast differentiation

Hyun Duk Jang1, Ji Hye Shin, Doo Ri Park

  • 1Division of Life and Pharmaceutical Sciences, Center for Cell Signaling and Drug Discovery Research, Ewha Womans University, Seoul 120-750, Korea.

The Journal of Biological Chemistry
|September 28, 2011
PubMed

Insights

Glycogen synthase kinase-3β (GSK-3β) inactivation is essential for osteoclast differentiation. Inhibiting GSK-3β impairs bone remodeling by affecting NFATc1 signaling, revealing a new role in bone metabolism.

Area of Science:

  • Bone Biology and Skeletal Diseases
  • Cell Signaling and Molecular Biology

Background:

  • Glycogen synthase kinase-3β (GSK-3β) is a key regulator of glycogen metabolism and osteoblast function.
  • The role of GSK-3β in osteoclast formation, a critical process in bone remodeling, is not well understood.

Purpose of the Study:

  • To investigate the role of GSK-3β in osteoclast differentiation and bone remodeling.
  • To elucidate the molecular mechanisms by which GSK-3β influences osteoclastogenesis.

Main Methods:

  • Utilized retroviral expression of GSK-3β mutants (constitutively active and inactive) in bone marrow macrophages.
  • Employed small interfering RNA (siRNA) for GSK-3β silencing and pharmacological inhibition.
  • Analyzed osteoclast differentiation, NFATc1 induction, Ca(2+) oscillations, and bone phenotypes in transgenic mice.

Main Results:

  • GSK-3β inactivation upon RANKL stimulation is crucial for osteoclast differentiation.
  • Constitutively active GSK-3β inhibited osteoclastogenesis, while inactive GSK-3β or silencing enhanced it.
  • GSK-3β activity regulates RANKL-mediated NFATc1 induction and Ca(2+) oscillations.
  • Transgenic mice overexpressing active GSK-3β exhibited osteopetrosis due to impaired osteoclast differentiation and NFATc1 signaling defects.

Conclusions:

  • GSK-3β acts as a negative regulator of osteoclast formation.
  • GSK-3β modulates NFATc1 signaling in response to RANKL, impacting bone remodeling.
  • Targeting GSK-3β offers a potential therapeutic strategy for bone diseases characterized by abnormal bone remodeling.

More Related Videos

Stimulation of Notch Signaling in Mouse Osteoclast Precursors08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...